The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]
  • No ClinVar Id was directly found from the curated document
  • 'cspec' property is found but contains no ID!

  • See Evidence submitted by expert panel for details.

Variant: NM_000261.2:c.864C>G

CA343725776

Gene: MYOC
Condition: primary open angle glaucoma
Inheritance Mode: Autosomal dominant inheritance
UUID: 2d92deec-b2bc-45e3-beb0-5e1ad1271a04
Approved on: 2023-02-15
Published on: 2023-02-15

HGVS expressions

NM_000261.2:c.864C>G
NC_000001.11:g.171636576G>C
CM000663.2:g.171636576G>C
NC_000001.10:g.171605716G>C
CM000663.1:g.171605716G>C
NC_000001.9:g.169872339G>C
NG_008859.1:g.21058C>G
ENST00000037502.11:c.864C>G
ENST00000637303.1:c.235-2054G>C
ENST00000638471.1:c.*202C>G
ENST00000037502.10:c.864C>G
ENST00000614688.1:c.864C>G
NM_000261.1:c.864C>G

Uncertain Significance

Met criteria codes 1
PM2_Supporting
Not Met criteria codes 14
PM5 PM4 PM6 BS3 BS1 BP4 BP7 PS2 PS1 PS3 PS4 BA1 PP1 PP3

Evidence Links 0

Expert Panel

Criteria Specification Information

Criteria Specifications for this VCEP
Evidence submitted by expert panel
Glaucoma VCEP
The c.864C>G variant in MYOC is a missense variant predicted to cause substitution of Isoleucine by Methionine at amino acid 288 (p.Ile288Met). This variant was not found in any population of gnomAD (v2.1.1), meeting the ≤ 0.0001 threshold set for PM2_Supporting in a population of at least 10,000 alleles. The REVEL score = 0.309, which was neither above nor below the thresholds for PP3 (≥ 0.7) or BP4 (≤ 0.15), predicting a damaging or benign impact on MYOC function. There was no functional evidence predicting a damaging or benign impact of this variant on MYOC function. Only 1 proband with primary open angle glaucoma had been reported (PMID: 21426841), not meeting the ≥ 2 probands threshold required to meet PS4_Supporting. In summary, this variant met the criteria to receive a score of 1 and to be classified as a variant of uncertain significance (uncertain significance classification range -1 to 5) for primary open angle glaucoma based on the ACMG/AMP criteria met, as specified by the ClinGen Glaucoma VCEP (v1, 12 Oct 2021): PM2_Supporting
Met criteria codes
PM2_Supporting
This variant was not found in any population of gnomAD (v2.1.1), meeting the ≤ 0.0001 threshold set for PM2_Supporting in a population of at least 10,000 alleles.
Not Met criteria codes
PM5
No other missense variants at this amino acid residue have been identified.
PM4
This variant does not cause a protein length change.
PM6
This variant has not been identified de novo.
BS3
No functional evidence has been found for this variant.
BS1
This criterion was not met as PM2_Supporting has been met.
BP4
The REVEL score = 0.309, which did not meet the ≤ 0.15 threshold required for BP4.
BP7
This is not a synonymous or non-coding variant.
PS2
This variant has not been identified de novo.
PS1
An established pathogenic variant causing this same amino acid change has not been identified.
PS3
No functional evidence has been found for this variant.
PS4
Only 1 proband with POAG had been reported (PMID: 21426841), not meeting the ≥ 2 probands threshold required to meet PS4_Supporting.
BA1
This criterion was not met as PM2_Supporting has been met.
PP1
No segregations have been reported for this variant.
PP3
The REVEL score = 0.309, which did not meet the ≥ 0.7 threshold for PP3.
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.